These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8562404)

  • 41. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in coagulation factors and platelet function in response to progestational agents.
    McGrath KM; Castaldi PA
    Haemostasis; 1975; 4(2):65-72. PubMed ID: 1205337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B; Zöller B; Hillarp A
    Haemostasis; 1996 Oct; 26 Suppl 4():301-14. PubMed ID: 8979136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
    Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
    Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Von Willebrand's disease.
    Hagedorn B
    JAMA; 1971 May; 216(6):991-5. PubMed ID: 4929581
    [No Abstract]   [Full Text] [Related]  

  • 46. Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels.
    Marcucci R; Abbate R; Fedi S; Gori AM; Brunelli T; Bruni V; Bucciantini S; Micheli S; Pepe G; Prisco D; Gensini GF
    Am J Clin Pathol; 1999 Jun; 111(6):769-72. PubMed ID: 10361512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII.
    Váradi K; Rosing J; Tans G; Schwarz HP
    Thromb Haemost; 1995 Apr; 73(4):730-1. PubMed ID: 7495090
    [No Abstract]   [Full Text] [Related]  

  • 48. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
    Fassett MJ; Bohn YC; Kuo J; Wing DA
    Am J Obstet Gynecol; 2000 Jun; 182(6):1433-6. PubMed ID: 10871461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy.
    Drury-Stewart DN; Lannert KW; Chung DW; Teramura GT; Zimring JC; Konkle BA; Gammill HS; Johnsen JM
    PLoS One; 2014; 9(11):e112935. PubMed ID: 25409031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function.
    Ocak G; Vossen CY; Lijfering WM; Verduijn M; Dekker FW; Rosendaal FR; Cannegieter SC
    Circulation; 2014 Feb; 129(6):683-91. PubMed ID: 24211824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The structure-function relationship of activated protein C. Lessons from natural and engineered mutations.
    Wildhagen KC; Lutgens E; Loubele ST; ten Cate H; Nicolaes GA
    Thromb Haemost; 2011 Dec; 106(6):1034-45. PubMed ID: 22072231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of von Willebrand factor on activation of factor VIII by factor Xa.
    Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ
    Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis.
    Alving BM; Comp PC
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1184-91. PubMed ID: 1415444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
    Legnani C; Cini M; Cosmi B; Mattarozzi S; Lo Manto G; Palareti G
    Thromb Haemost; 2004 Apr; 91(4):712-8. PubMed ID: 15045132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to activated protein C decreases throughout pregnancy.
    Benedetto C; Marozio L; Tavella AM; Maulà V; Carmignani D; Curti A
    Acta Obstet Gynecol Scand; 2002 Nov; 81(11):1028-32. PubMed ID: 12421170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can von Willebrand disease be investigated on combined hormonal contraceptives?
    Dumont T; Allen L; Kives S
    J Pediatr Adolesc Gynecol; 2013 Jun; 26(3):138-41. PubMed ID: 22206686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.